Natural history of corticosteroid-induced lipodystrophy: a prospective follow-up of 37 patients;Histoire naturelle de la lipodystrophie cervicofaciale cortico-induite : suivi prospectif d'une cohorte de 37 patients

Revue de Medecine Interne

Volumn 28, Issue 12, 2007, Pages 825-831

  Fardet, L ^a,b   Flahault, A ^b   Kettaneh, A ^a   Tiev, K P ^a   Toledano C ^a   Cabane, J ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

Author keywords

Adverse events; Corticosteroids; Lipodystrophy

Indexed keywords

PREDNISONE; C REACTIVE PROTEIN; CORTICOSTEROID;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; INCIDENCE; LIPODYSTROPHY; LONG TERM CARE; MALE; PHOTOGRAPHY; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; METABOLISM; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; GIANT CELL ARTERITIS; HUMANS; LIPODYSTROPHY; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 36249023174     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.06.002     Document Type: Article

References (23)

1. Walsh L.J., Wong C.A., Pringle M., and Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313 (1996) 344-346
2. Van Staa T.P., Leufkens H.G., Abenhaim L., Begaud B., Zhang B., and Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 93 (2000) 105-111
3. Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis. Chest 48 (1965) 287-290
4. Jover J.A., Hernandez-Garcia C., Morado I.C., Vargas E., Banares A., and Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 134 (2001) 106-114
5. Covar R.A., Leung D.Y., McCormick D., Steelman J., Zeitler P., and Spahn J.D. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J. Allergy Clin. Immunol. 106 (2000) 651-659
6. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. Sous presse, J. Am. Acad. Dermatol.
7. Conn H.O., and Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J. Intern. Med. 236 (1994) 619-632
8. Buchman A.L. Side effects of corticosteroid therapy. J. Clin. Gastroenterol. 33 (2001) 289-294
9. Bergrem H., Jervell J., and Flatmark A. Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Kidney Int. 27 (1985) 459-464
10. Lipnick R.N., Morales A., Getson P.R., White P.H., and Soldin S.J. Use of a radioreceptor assay in the assessment of cushingoid features in patients with juvenile rheumatic diseases. Ther. Drug Monit. 14 (1992) 169-172
11. Bar-Meir S., Chowers Y., Lavy A., Abramovitch D., Sternberg A., Leichtmann G., et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 115 (1998) 835-840
12. Campieri M., Ferguson A., Doe W., Persson T., and Nilsson L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 41 (1997) 209-214
13. Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 33 (1990) 1122-1128
14. Morrison E., Crosbie D., and Capell H.A. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 42 (2003) 1247-1250
15. Fardet L., Flahault A., Kettaneh A., Tiev K.P., Généreau G., Tolédano C., et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's feeling. Br. J. Dermatol. 157 1 (2007) 142-148
16. Benet L.Z., Frey F.J., Amend Jr. W.J., Lozada F., and Frey B.M. Endogenous and exogenous glucocorticoids in cushingoid patients. Drug Intell. Clin. Pharm. 16 (1982) 863-868
17. Frey F.J., Amend Jr. W.J., Lozada F., Frey B.M., and Benet L.Z. Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. J. Clin. Endocrinol. Metab. 53 (1981) 1076-1080
18. Gambertoglio J.G., Vincenti F., Feduska N.J., Birnbaum J., Salvatierra Jr. O., and Amend Jr. W.J. Prednisolone disposition in cushingoid and non-cushingoid kidney transplant patients. J. Clin. Endocrinol. Metab. 51 (1980) 561-565
19. Kozower M., Veatch L., and Kaplan M.M. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. J. Clin. Endocrinol. Metab. 38 (1974) 407-412
20. Fardet L., Flahault A., Kettaneh A., Tiev K.P., Toledano C., Lebbe C., et al. Corticothérapie systémique et alimentation : suivi des recommandations diététiques et relation entre apports alimentaires et apparition d'une lipodystrophie. Rev. Med. Interne 28 (2007) 284-288
21. Galli M., Veglia F., Angarano G., Santambrogio S., Meneghini E., Gritti F., et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J. Acquir. Immune Defic. Syndr. 34 (2003) 58-61
22. Misra A., and Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 82 (2003) 129-146
23. Young J., Rickenbach M., Weber R., Furrer H., Bernasconi E., Hirschel B., et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir. Ther. 10 (2005) 73-81